 Herein we report the synthesis of novel 2 substituted styrylquinazolines conjugated with aniline or sulfonamide moieties anticipated to act as potent anticancer therapeutic agents through preferential EGFR inhibition . In doing so all the synthesized compounds were screened for their

@highlight Styrylquinazolines conjugated with aniline or sulfonamides targeting EGFR were synthesized.
@highlight Anticancer screening MTT EGFR A549 anti proliferative activity were evaluated.
@highlight Cell cycle studies were demonstrated.
@highlight ADMET and EGFR Molecular docking studies were performed.
